Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials

Diabetes Research and Clinical Practice

Volumn 103, Issue 2, 2014, Pages 269-275

  Monami, Matteo ^a   Dicembrini, Ilaria ^a   Nardini, Camilla ^a   Fiordelli, Irene ^a   Mannucci, Edoardo ^a  

^a Careggi Teaching Hospital   (Italy)

Author keywords

Glucagon like peptide 1 receptor agonists; Meta analysis; Pancreatitis

Indexed keywords

BIPHASIC INSULIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; ALBIGLUTIDE; ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LIRAGLUTIDE; PEPTIDE; TASPOGLUTIDE; VENOM; ZP10A PEPTIDE;

DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; INCIDENCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; AGONISTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PANCREATITIS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; VENOMS;

EID: 84895787341     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.01.010     Document Type: Review

References (16)

1. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010, 123(March (3 Suppl.)):S28-S37.2.
2. Vilsbøll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344(January):d7771. 10.1136/bmj.d7771.
3. Mannucci E., Dicembrini I. Incretin-based therapies and cardiovascular risk. Curr Med Res Opin 2012, 28(May (5)):715-721.
4. Mundil D., Cameron-Vendrig A., Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 2012, 9(April (2)):95-108.
5. Monami M., Cremasco F., Lamanna C., Colombi C., Desideri C.M., Iacomelli I., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:215764.
6. Marso S.P., Lindsey J.B., Stolker J.M., House J.A., Martinez Ravn G., Kennedy K.F., et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011, 8(July (3)):237-240.
7. Singh S., Chang H.Y., Richards T.M., Weiner J.P., Clark J.M., Segal J.B. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013, 173(7):534-539.
8. Elashoff M., Matveyenko A.V., Gier B., Elashoff R., Butler P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141(July (1)):150-156.
9. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
10. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
11. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101.
12. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
13. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. PRISMA Group, W64.
14. Drucker D.J., Sherman S.I., Gorelick F.S., Bergenstal R.M., Sherwin R.S., Buse J.B. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33(February (2)):428-433.
15. Garg R., Chen W., Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010, 33(November (11)):2349-2354.
16. Dore D.D., Seeger J.D., Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25(4):1019-1027.